Ardelyx

Ardelyx, Inc. is a biopharmaceutical company. engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ardelyx reports strong Q4 earnings, poised for product expansion

Ardelyx's Q4 performance reflects revenue growth, improved financial efficiency, and progress towards expanding its product portfolio.
While facing challenges such as regulatory processes and market competition, Ardelyx's strengths lie in successful product launches and a proactive commercial strategy.
Opportunities for Ardelyx include leveraging positive feedback for XPHOZAH, raising additional funds for growth, and diversifying revenue through new product launches.

Ardelyx reports sales growth, readies XPHOZAH launch amid challenges

Ardelyx showed strong sales growth for IBSRELA and is poised for the XPHOZAH launch
Financially, the company raised significant funds and maintains a healthy cash position
Challenges include managing expenses and improving profitability amidst losses
Opportunities lie in upcoming product launches and optimizing financial operations

Ardelyx reports strong Q2 performance amidst legislative challenges and growth opportunities

Ardelyx's Q2 performance reflects growth in IBSRELA sales and overall revenue, despite incurring a net loss.
The company faces challenges from pending legislation and financial burdens related to XPHOZAH launch preparation.
Opportunities lie in the potential of XPHOZAH launch, market reception of IBSRELA, and addressing legislative impacts.

Ardelyx reports strong Q3 earnings, poised for successful XPHOZAH launch

Ardelyx's Q3 performance reflects financial strength and positive market reception for IBSRELA.
Challenges in pricing strategy and market competition require strategic planning for XPHOZAH's launch.
Opportunities lie in leveraging financial stability, physician interest, and promotional activities for XPHOZAH success.
The company's commitment to patient access and learnings from IBSRELA will drive future growth and market penetration.

Ardelyx reports strong revenue growth driven by IBSRELA success

Ardelyx is strategically investing in growth, focusing on sustaining momentum for its products. The company is well-resourced and optimistic about the future performance of IBSRELA and XPHOZAH. Despite challenges in operating expenses, Ardelyx remains committed to its commercialization efforts.

Ardelyx reports robust Q1 performance driven by XPHOZAH success

Ardelyx's Q1 2024 earnings call showcased strong revenue growth, particularly driven by XPHOZAH and IBSRELA. The company's cash position remains healthy, and there is a clear focus on expanding market reach and driving adoption of key therapies.

Ardelyx reports robust Q2 earnings, focuses on patient access advocacy

Ardelyx's Q2 2024 performance reflects strong revenue growth driven by IBSRELA and XPHOZAH, with a focus on shareholder value and patient access advocacy. While facing challenges in legal battles and expense management, the company is poised to capitalize on opportunities through sales force expansion and market differentiation strategies.

Ardelyx (ARDX) reports robust Q3 earnings, navigates Medicare coverage challenges

Ardelyx's Q3 earnings call highlighted strong financial performance, success of key medications, and strategies to address Medicare coverage challenges. The company's focus on patient access, commitment to therapy availability, and positive market impact showcase its growth potential and resilience in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

San Diego, California--(Newsfile Corp. - August 24, 2021) -  Robbins Geller Rudman & Dowd LLP announces that purchasers of Ardelyx Inc. (NASDAQ: ARDX) securities between August 6, 2020 and July 19, 2021, inclusive ("Class Period"), have until September 28, 2021 to seek appointment as lead plaintiff in the Ardelyx class action lawsuit. The Ardelyx class action lawsuit (Strezsak v. Ardelyx Inc., No. 21-cv-05868) charges Ardelyx and certain of its top executives with violations of...

DEADLINE: Investors With Substantial Losses Have Opportunity to Lead the Ardelyx Inc. Class Action Lawsuit - ARDX

James River Group Holdings

Oatly

NEW YORK, NY / ACCESSWIRE / August 24, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

SHAREHOLDER ALERT: JRVR OTLY ARDX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

View

Zymergen

NEW YORK, NY / ACCESSWIRE / August 23, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

SHAREHOLDER ALERT: ARDX ZY VIEW: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Annovis Bio

Royal Philips

NEW YORK, NY / ACCESSWIRE / August 23, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ARDX, PHG and ANVS

Camber Energy

Phunware Inc

Making a penny stocks watchlist this week? Check these 3 out The post Top Penny Stocks To Buy Now?

Top Penny Stocks To Buy Now? 3 For Your Watchlist This Week

Piedmont Lithium

NEW YORK, NY / ACCESSWIRE / August 22, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PLL, ARDX and ANVS

New York, New York--(Newsfile Corp. - August 21, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and July 19, 2021, inclusive (the "Class Period") of the important September 28, 2021 lead plaintiff deadline.SO WHAT: If you purchased Ardelyx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...

Rosen, Trusted Investor Counsel, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

New York, New York--(Newsfile Corp. - August 20, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Ardelyx, Inc. (NASDAQ: ARDX).Shareholders who purchased shares of ARDX during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/ardelyx-inc-loss-submission-form/?id=18761&from=5

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Ardelyx, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 28, 2021 - (ARDX)

New York, New York--(Newsfile Corp. - August 17, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and July 19, 2021, inclusive (the "Class Period") of the important September 28, 2021 lead plaintiff deadline.SO WHAT: If you purchased Ardelyx securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

ROSEN, A LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors With Losses Over $100K to Secure Counsel Before Important September 28 Deadline in Securities Class Action - ARDX

360 Finance Inc - ADR

Full Truck Alliance Co Ltd

NEW YORK, NY / ACCESSWIRE / August 17, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.

CLASS ACTION UPDATE for YMM, QFIN and ARDX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

RADNOR, Pa., Aug. 16, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against Ardelyx Inc. (NASDAQ: ARDX) ("Ardelyx") on behalf of those who purchased or acquired Ardelyx securities between August 6, 2020 and July 19, 2021 , inclusive (the "Class Period").

Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Ardelyx Inc. (ARDX)

Boston, Massachusetts--(Newsfile Corp. - August 16, 2021) -  Block & Leviton announces that a class action lawsuit has been filed against Ardelyx Inc. (NASDAQ: ARDX) and certain of its officers for securities law violations. Investors who purchased shares between August 6, 2020 and July 19, 2021 and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/ardx.What is this all about?On...

LAWSUIT FILED: Ardelyx Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Ardelyx (ARDX) Stock?

Coinbase

Concho Resources

NEW YORK, NY / ACCESSWIRE / August 16, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of COIN, ARDX and CXO

Radnor, Pennsylvania--(Newsfile Corp. - August 13, 2021) -  The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Ardelyx Inc. (NASDAQ: ARDX) ("Ardelyx") on behalf of those who purchased or acquired Ardelyx securities between August 6, 2020 and July 19, 2021, inclusive (the "Class Period").Investor Deadline Reminder: Investors who purchased or acquired Ardelyx securities during the Class Period may, no...

Shareholder Alert: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Ardelyx Inc. of Securities Class Action Lawsuit

Shares of Ardelyx (NASDAQ:ARDX) moved higher by 2.0% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 60.71% over the past year to ($0.45), which missed the estimate of ($0.36).

Ardelyx: Q2 Earnings Insights

Ardelyx Reports Second Quarter 2021 Financial Results

CarLotz

NEW YORK, NY / ACCESSWIRE / August 13, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.

CLASS ACTION UPDATE for LOTZ, OTLY and ARDX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

RADNOR, Pa.--(BUSINESS WIRE)---- $ARDX #classaction--ARDX CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Ardelyx Inc. Shareholders of Securities Fraud Class Action Lawsuit

ARDX CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Ardelyx Inc. Shareholders of Securities Fraud Class Action Lawsuit

NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) and certain of its officers.   The class action was filed in the United States District Court for the Northern District of California, Oakland Division, and docketed under 21-cv-06228.

Pomerantz Law Firm Announces the Filing of a Class Action Against Ardelyx, Inc. and Certain Officers - ARDX

New York, New York--(Newsfile Corp. - August 12, 2021) -  Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Ardelyx, Inc. (NASDAQ: ARDX).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/ardelyx-inc-loss-submission-form/?id=18495&from=5

ARDX Lawsuit Filed: Jakubowitz Law Pursues Claims on Behalf of Ardelyx, Inc. Shareholders

NEW YORK, Aug. 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX

NEW YORK, Aug. 11, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and July 19, 2021, inclusive (the "Class Period") of the important September 28, 2021 lead plaintiff deadline. SO WHAT: If you purchased Ardelyx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

RADNOR, Pa., Aug. 11, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed against Ardelyx Inc. (NASDAQ: ARDX) ("Ardelyx") on behalf of those who purchased or acquired Ardelyx securities between August 6, 2020 and July 19, 2021 , inclusive (the "Class Period").

Ardelyx Inc. Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Ardelyx Inc.

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of all purchasers of Ardelyx Inc. securities (NASDAQ: ARDX) between August 6, 2020 and July 19, 2021, for violations of the Securities Exchange Act of 1934. Ardelyx is a biopharmaceutical company that develops medicines for people with cardiorenal disease. Ardelyx's lead drug candidate is tenapanor, a medicine for the control of serum phosphorus in adult patients with chron

News for Ardelyx Stock (ARDX)